News 2020-04-21
Porton Successfully Receives Third US FDA Inspection.
We are proud to announce that Porton’s cGMP-compliant Erlang site located in the Chonqing Metro Region, China passed a 4-day general inspection [April 24-28, 2016] by the US FDA without any Form 483 observations. This is the third successful inspection of our China sites by the US FDA since 2013. Supported by a unified Quality Management System and Corporate Quality Group, Porton’s production sites continue to reliably deliver efficient and high-quality manufacturing solutions across the full life cycle for our valued global customers. Learn how we can help you – contact us today!
Note: Porton is still waiting for FDA’s official written document “EIR” (Establishment Investigation Report) of this Erlang inspection, more information shall be disclosed in compliance with China listed-company disclosure rules accordingly.
Note: Porton is still waiting for FDA’s official written document “EIR” (Establishment Investigation Report) of this Erlang inspection, more information shall be disclosed in compliance with China listed-company disclosure rules accordingly.
Others
More
News 2025-04-16
Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy
April 12, 2025 - Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).
News 2025-04-11
Porton Newsletter - March 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities
